Drugs / C-TIL051
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05676749 | Feb 2024 → Dec 2025 | non-small cell lung carcinoma | AbelZeta Inc. | Terminated | No outcome recorded Stop: Business |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2023-09-27 | Nektar Therapeutics | Nektar Therapeutics Announces New Clinical Study Collaboration with Cellular Biomedicine Group Inc. to Evaluate NKTR-255 in Combination with C-TIL051 in Advanced Non-Small Cell Lung Cancer nektar.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | C-TIL051 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05676749 ↗ |
| Modality | Cell therapy | “tumor infiltrating lymphocytes (known as C-TIL051)” NCT05676749 ↗ |
| Route | Other | “C-TIL051 will then be infused on day 0” NCT05676749 ↗ |